Global private investor The Riverside Company has invested in PPM Advisory Group and OrtleyBio (collectively PPM)
PPM provides scientific operations and communications services to global biopharmaceutical companies with a focus on oncology and haematology therapeutic areas. The company leverages its deep scientific expertise to support customers across various stages of the drug life cycle to better educate and inform healthcare professionals, medical science liaisons and commercial sales representatives.
PPM is an add-on investment to Riverside’s platform Red Nucleus (RN), a premier provider of learning, performance and process solutions for the life sciences industry. This is RN’s fifth add-on acquisition since Riverside’s investment in December 2019, having invested in Pyxa Systems (DirectusPRO), LSTI, INVIVO Communications and iTakeControl.
“We’re thrilled to partner with the PPM team, complementing Red Nucleus with a science-first provider of commercialisation and medical communications solutions,” says Riverside Co-Chief Investment Officer (RCAF) Peter Tsang. “With the addition of PPM, we plan to further expand RN’s products, services and customer base and bolster its scientific expertise in critical therapeutic areas such as oncology.”
Source: Private Equity Wire
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.